Abstract：
Statin use may exacerbate exercise-induced skeletal muscle injury caused by reduced coenzyme Q10 (CoQ10) levels, which are postulated to produce mitochondrial dysfunction.
We determined the effect of prolonged moderate-intensity exercise on markers of muscle injury in statin users with and without statin-associated muscle symptoms. We also examined the association between leukocyte CoQ10 levels and muscle markers, muscle performance, and reported muscle symptoms.
Symptomatic (n = 35; age 62 ± 7 years) and asymptomatic statin users (n = 34; age 66 ± 7 years) and control subjects (n = 31; age 66 ± 5 years) walked 30, 40, or 50 km/d for 4 consecutive days. Muscle injury markers (lactate dehydrogenase, creatine kinase, myoglobin, cardiac troponin I, and N-terminal pro-brain natriuretic peptide), muscle performance, and reported muscle symptoms were assessed at baseline and after exercise. Leukocyte CoQ10 was measured at baseline.
All muscle injury markers were comparable at baseline (P > 0.05) and increased following exercise (P < 0.001), with no differences in the magnitude of exercise-induced elevations among groups (P > 0.05). Muscle pain scores were higher at baseline in symptomatic statin users (P < 0.001) and increased similarly in all groups following exercise (P < 0.001). Muscle relaxation time increased more in symptomatic statin users than in control subjects following exercise (P = 0.035). CoQ10 levels did not differ among symptomatic (2.3 nmol/U; IQR: 1.8-2.9 nmol/U), asymptomatic statin users (2.1 nmol/U; IQR: 1.8-2.5 nmol/U), and control subjects (2.1 nmol/U; IQR: 1.8-2.3 nmol/U; P = 0.20), and did not relate to muscle injury markers, fatigue resistance, or reported muscle symptoms.
Statin use and the presence of statin-associated muscle symptoms does not exacerbate exercise-induced muscle injury after moderate exercise. Muscle injury markers were not related to leukocyte CoQ10 levels. (Exercise-induced Muscle Damage in Statin Users; NCT05011643).
We determined the effect of prolonged moderate-intensity exercise on markers of muscle injury in statin users with and without statin-associated muscle symptoms. We also examined the association between leukocyte CoQ10 levels and muscle markers, muscle performance, and reported muscle symptoms.
Symptomatic (n = 35; age 62 ± 7 years) and asymptomatic statin users (n = 34; age 66 ± 7 years) and control subjects (n = 31; age 66 ± 5 years) walked 30, 40, or 50 km/d for 4 consecutive days. Muscle injury markers (lactate dehydrogenase, creatine kinase, myoglobin, cardiac troponin I, and N-terminal pro-brain natriuretic peptide), muscle performance, and reported muscle symptoms were assessed at baseline and after exercise. Leukocyte CoQ10 was measured at baseline.
All muscle injury markers were comparable at baseline (P > 0.05) and increased following exercise (P < 0.001), with no differences in the magnitude of exercise-induced elevations among groups (P > 0.05). Muscle pain scores were higher at baseline in symptomatic statin users (P < 0.001) and increased similarly in all groups following exercise (P < 0.001). Muscle relaxation time increased more in symptomatic statin users than in control subjects following exercise (P = 0.035). CoQ10 levels did not differ among symptomatic (2.3 nmol/U; IQR: 1.8-2.9 nmol/U), asymptomatic statin users (2.1 nmol/U; IQR: 1.8-2.5 nmol/U), and control subjects (2.1 nmol/U; IQR: 1.8-2.3 nmol/U; P = 0.20), and did not relate to muscle injury markers, fatigue resistance, or reported muscle symptoms.
Statin use and the presence of statin-associated muscle symptoms does not exacerbate exercise-induced muscle injury after moderate exercise. Muscle injury markers were not related to leukocyte CoQ10 levels. (Exercise-induced Muscle Damage in Statin Users; NCT05011643).
摘要：
背景：他汀类药物的使用可能会加剧由辅酶Q10（CoQ10）水平降低引起的运动诱发的骨骼肌损伤，据推测会产生线粒体功能障碍。
目的：我们确定了长期中等强度运动对有或没有他汀类药物相关肌肉症状的他汀类药物使用者肌肉损伤标志物的影响。我们还检查了白细胞CoQ10水平和肌肉标志物之间的关联，肌肉性能，并报告了肌肉症状。
方法：有症状（n=35；年龄62±7岁）和无症状他汀类药物使用者（n=34；年龄66±7岁）和对照组（n=31；年龄66±5岁）连续4天步行30、40或50km/d。肌肉损伤标志物（乳酸脱氢酶，肌酸激酶，肌红蛋白,心肌肌钙蛋白I,和N末端脑利钠肽前体)，肌肉性能，和报告的肌肉症状在基线和运动后进行评估。在基线测量白细胞CoQ10。
结果：所有肌肉损伤标志物在基线时具有可比性（P>0.05），运动后增加（P<0.001），各组运动诱发的升高幅度无差异(P>0.05)。有症状的他汀类药物使用者在基线时肌肉疼痛评分较高（P<0.001），运动后所有组的肌肉疼痛评分均相似（P<0.001）。有症状的他汀类药物使用者的肌肉放松时间比运动后的对照组增加更多（P=0.035）。CoQ10水平在症状之间没有差异（2.3nmol/U;IQR：1.8-2.9nmol/U），无症状他汀类药物使用者（2.1nmol/U；IQR：1.8-2.5nmol/U），和对照组（2.1nmol/U；IQR：1.8-2.3nmol/U；P=0.20），与肌肉损伤标记无关，抗疲劳性，或报告肌肉症状。
结论：使用他汀类药物和他汀类药物相关肌肉症状的存在并不会加剧适度运动后的运动性肌肉损伤。肌肉损伤标志物与白细胞CoQ10水平无关。（他汀类药物使用者的运动诱发肌肉损伤；NCT05011643）。
目的：我们确定了长期中等强度运动对有或没有他汀类药物相关肌肉症状的他汀类药物使用者肌肉损伤标志物的影响。我们还检查了白细胞CoQ10水平和肌肉标志物之间的关联，肌肉性能，并报告了肌肉症状。
方法：有症状（n=35；年龄62±7岁）和无症状他汀类药物使用者（n=34；年龄66±7岁）和对照组（n=31；年龄66±5岁）连续4天步行30、40或50km/d。肌肉损伤标志物（乳酸脱氢酶，肌酸激酶，肌红蛋白,心肌肌钙蛋白I,和N末端脑利钠肽前体)，肌肉性能，和报告的肌肉症状在基线和运动后进行评估。在基线测量白细胞CoQ10。
结果：所有肌肉损伤标志物在基线时具有可比性（P>0.05），运动后增加（P<0.001），各组运动诱发的升高幅度无差异(P>0.05)。有症状的他汀类药物使用者在基线时肌肉疼痛评分较高（P<0.001），运动后所有组的肌肉疼痛评分均相似（P<0.001）。有症状的他汀类药物使用者的肌肉放松时间比运动后的对照组增加更多（P=0.035）。CoQ10水平在症状之间没有差异（2.3nmol/U;IQR：1.8-2.9nmol/U），无症状他汀类药物使用者（2.1nmol/U；IQR：1.8-2.5nmol/U），和对照组（2.1nmol/U；IQR：1.8-2.3nmol/U；P=0.20），与肌肉损伤标记无关，抗疲劳性，或报告肌肉症状。
结论：使用他汀类药物和他汀类药物相关肌肉症状的存在并不会加剧适度运动后的运动性肌肉损伤。肌肉损伤标志物与白细胞CoQ10水平无关。（他汀类药物使用者的运动诱发肌肉损伤；NCT05011643）。
